Lastly as the majority of GLP-1 RAs in this study were semaglutide, this may not apply to all GLP-1 RAs and additionally, because the analysis excluded over 26,000 patients who could not be matched, the results may not apply to the full spectrum of patients taking these drugs in the real world, particularly those with more complex health profiles. MNT spoke with David I
Download Our Shocking FREE REPORT
Nearly a dozen oral GLP-1 molecules are in various stages of development at Chinese pharma firms, including Hengrui, Huadong, Innovent Biologics and Ascletis
Meta-analyses of randomised controlled trials (RCTs) also confirm that energy-restricted MD interventions yield greater weight loss than control or low-fat diets, particularly when combined with increased physical activity [116]
Tirzepatide reduces glucagon
The impact of bariatric and metabolic surgery on cancer development